Malignancy in Long-Standing Perianal Fistulizing Crohn's Disease: Too Little, Too Late.

Dig Dis SciApr 13, 2026 (epub)

Alisha Goyal, Gaurav Syal, Phillip Fleshner et al.

✦ AI-curated · Sources linked

Case in brief

A 71-year-old man with nearly 50 years of untreated perianal fistulizing Crohn’s disease had recurrent abscesses, sepsis, and fistulizing disease. Progressive enlargement of a complex perianal abscess and new pelvic collections raised concern for malignant transformation, but imaging could not reliably distinguish cancer from active inflammation. Examination under anesthesia with drainage and biopsy revealed mucinous adenocarcinoma arising in a chronic fistula. His condition deteriorated rapidly, precluding oncologic treatment, and he was transitioned to hospice.

What made this case unusual

Mucinous adenocarcinoma arose within a chronic perianal fistula after nearly 50 years of Crohn’s disease; progressive abscesses and pelvic collections initially overlapped with inflammatory disease, delaying diagnostic clarity.

Diagnostic / clinical pearl

In long-standing perianal fistulizing Crohn’s disease, persistent or new symptoms and progressive collections warrant evaluation for malignancy; imaging may not distinguish it from inflammation, and examination under anesthesia with biopsy can establish the diagnosis.

Why it matters

The case underscores the diagnostic challenge and poor outcome described for fistula-associated cancer, while formal screening guidelines are lacking.

Source

Published in Dig Dis Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.